• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

3v.org

Venture Capital Matters

  • Pitch a Startup
    • Make a Contribution
  • Market Reports
  • Technologies
    • Technology Events
  • Domain Names for Startups
  • About
  • Contact

Alladapt Immunotherapeutics Secures $60 Million in Series C Financing for Development of Food Allergy Therapeutics

February 20, 2020 By admin Leave a Comment

Alladapt Immunotherapeutics Inc., a private biopharmaceutical company focused on the development of prescription therapeutics to address food allergy, today announced the completion of a $60 million Series C financing. The round was led by Gurnet Point Capital, a private investment fund, which has been involved with Alladapt since the Company’s founding in 2018.

Proceeds from the financing will enable the initial clinical development of ADP101, a proprietary oral immunotherapy drug candidate that is being advanced for the mitigation of food allergy provoked by either single or multiple proteins from a wide-ranging set of foods.

“Food allergy occurs when the body’s immune system becomes inappropriately sensitive to certain food proteins, and reacts upon exposure with severe or sometimes life-threatening consequences,” said Kari Nadeau, MD, PhD, scientific inventor of ADP101 and co-founder of Alladapt. “It is a highly burdensome, chronic disease that has grown to epidemic proportions in a generation and causes significant disability and suffering for millions of people worldwide. Nine common food groups are associated with more than 90 percent of food allergic reactions and, unfortunately, therapeutic options to address this disease remain inadequate. I am excited that Alladapt is working to develop next generation therapeutic interventions for patients intended to address this disease quite broadly.”

“After a great deal of progress, we are preparing to initiate a clinical trial later this year with our first therapeutic program, bringing us one step closer to our goal of developing a novel oral prescription therapy that may simultaneously target food allergy triggered by an expansive set of antigens,” said Chief Executive Officer and co-founder, Ashley Dombkowski, PhD. “We have an outstanding in-house team of industry experts, have assembled distinguished scientific advisors with complementary expertise, and we are backed by a value-added syndicate of investors led by Gurnet Point Capital. Importantly, we are including the patient perspective in key aspects of our development program, from the formulation of our product candidate to the details of our clinical development plans.”

Chris Viehbacher, the Managing Partner at Gurnet Point Capital and founding Board Member at Alladapt added, “We are pleased to lead this financing and support the team at Alladapt Immunotherapeutics in the development of such a novel, needed therapy. The Gurnet Point model enables us to contribute not only capital but also significant ‘bench to bedside’ expertise focused on improving human health in important ways. We are honored to be joined in this financing by other healthcare experts and by food allergy families who share our conviction that Alladapt’s approach has the potential to meaningfully improve patient access to effective options to manage this underserved disease.”

Providing medical leadership at Alladapt is Dana McClintock, MD, Chief Medical Officer. Dr. McClintock joined Alladapt in 2018 from Genentech where she served most recently as Global Head of the Office of I2O Innovation. Her past experience encompasses the breadth of clinical and product development, from early stage research through post-marketing, across immunology, infectious disease and ophthalmology.

Serving alongside Dr. Dombkowski on the Board of Directors are:

Greg Horn, Managing Director at William Hood and Company and CEO of Specialty Nutrition Consulting
Sophie Kornowski, PharmD, Senior Partner at Gurnet Point Capital, former Executive Vice-President of Roche Partnering
Christopher Viehbacher, Managing Partner at Gurnet Point Capital and former Chief Executive Officer of Sanofi
The Company’s clinical and scientific advisors are:

Eugene Bauer, MD, Co-founder and CMO of Dermira, former Dean of the School of Medicine and Vice President for Medical Affairs, Stanford University
Sharon Chinthrajah, MD, Clinical Associate Professor of Medicine, Pediatrics Immunology and Allergy at Stanford
Thomas Fleming, PhD, Professor of Biostatistics at University of Washington
Susannah Fox, Health and Technology Researcher; Former Chief Technology Officer, U.S. Department of Health and Human Services
Ruchi Gupta, MD, Professor of Pediatrics and Medicine at Northwestern Medicine, Director of the Center for Food Allergy & Asthma Research at Northwestern’s Institute for Public Health and Medicine, attending physician at Ann & Robert H. Lurie Children’s Hospital Chicago
Kari Nadeau, MD, PhD, Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Section Chief of Allergy and Asthma at the Stanford School of Medicine, Professor under the Naddisy Family Foundation
Dale Umetsu, MD, PhD, Adjunct Clinical Professor of Medicine, Pulmonary & Critical Care Medicine at Stanford
Christopher T. Walsh, PhD, Emeritus Faculty, Harvard Medical School, Advisor to Stanford’s ChEM-H Institute, Scientific Advisory Board Member to the Broad Institute of Harvard and MIT, Senior Associate Member to the Broad Institute of Harvard and MIT, former President of the Dana-Farber Cancer Institute
In addition to Gurnet Point Capital, the investment syndicate includes participation from healthcare business leaders and an engaged consortium of families from the food allergy community including Martha Goldberg Aronson & Dan Aronson, Justine Stamen Arrillaga & John Arrillaga, Denise & Dave Bunning, Michele & Tim Barakett, Katherine Collins, Equilibra Partners Management LLC, Linda & Bill Friend, Kim & Alan Hartman, Melissa & Scott Kepner, Rebecca & Sasha Lainovic, Bruce A. Menin, Shirley & Mike Orsak, Melanie & Tom Staggs, Jeff Weiner, Anne Wojcicki, and Stephanie Winston Wolkoff. Alladapt has been backed since inception by this syndicate.

About Food Allergy
Food Allergy is a serious, chronic disease in which the body’s immune system reacts inappropriately to food proteins with rapid, severe, and potentially life-threatening consequences. The disease affects 32 million people in the United States alone.1, 2 Nine common food groups are associated with more than 90 percent of food allergic reactions. The specific foods and combinations that provoke an allergic reaction can vary widely between people, resulting in potentially tens of thousands of unique presentations of the disease.

About Alladapt Immunotherapeutics
Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy. The Company’s lead program, ADP101, is being advanced as a broad spectrum oral immunotherapy treatment to mitigate food allergy triggered by single or multiple proteins from an expansive set of common allergens.

Alladapt was co-founded in 2018 by allergist and protein biochemist Kari Nadeau, MD, PhD and biotechnology entrepreneur, Ashley Dombkowski, PhD. Academic clinical research conducted by Dr. Nadeau has demonstrated that a food allergic immune system in an individual person can be receptive to remodeling by gradually increasing exposure under tightly controlled clinical supervision to the proteins that activate the inappropriate cascade of reactions. This work, combined with research illuminating disease mechanisms and pathways, led the founders to envision a biopharmaceutical intervention capable of addressing food allergy provoked by a wide-ranging set of antigens.

For more information, please visit the Company’s website at www.alladapt.com.

About Gurnet Point Capital
Gurnet Point Capital (GPC) is a unique health care fund founded by Ernesto Bertarelli and led by Christopher A. Viehbacher, who, together, have decades of expertise in an industry for which they share a passion, both as chief executives and as investors. With an initial allocation of $2 billion, GPC is investing long-term capital and supporting entrepreneurs in building a new generation of companies. Based in Cambridge, MA, its remit is global, encompassing life sciences and medical technologies. The fund invests across all stages of product development through to commercialisation and does so with an approach that is a hybrid of venture and private equity investing strategies. This approach is governed by a guiding tenet that even the earliest of technologies must present a clear commercial case, benefiting both patients and the healthcare system as a whole.

References
1 Gupta, R. S., Warren, C. M., Smith, B. M., Jiang, J., Blumenstock, J. A., Davis, M. M., et al. (2019). “Prevalence and Severity of Food Allergies Among US Adults.” JAMA Netw Open 2(1): e185630.

2 Gupta, R. S., Warren, C. M., Smith, B. M., Blumenstock, J. A., Jiang, J., Davis, M. M., et al. (2018). “The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States.” Pediatrics 142(6).

Source: Alladapt Immunotherapeutics, Inc.

Filed Under: PR Tagged With: Alladapt Immunotherapeutics, Food Allergy Therapeutics

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

Wall Street snapped up thousands of homes across America
Take-Two will acquire Zynga for $12.7B
Market Size Matters
AIML.ag: AIML is the future of agriculture
Autonomous manufacturing: solving a $200 billion problem
DeFiRetailing.com (DeFi Retailing): DeFi will change retail as we know it
NLPAIML.com (NLP AIML): NLP meets AIML

Market Research Media

InfluenceMgmt.com (Influence Management): How to get others to adopt your recommendation
ImpactfulTrends.com (Impactful Trends): Trends to Watch in 2022
Web3.ag: Not everyone is happy with decentralization of Internet
KeyEditorials.com: Editorial art can be visually striking
NFT sales hit 12-month low
White House hosts tech summit to discuss open-source security after Log4j
Smart Media Streamer is Better Than Smart TV

Secondary Sidebar

Technologies

Digital trends shaping the future of work
Ancient Sustainability Technologies
Intel to Acquire Tower Semiconductor for $5.4 Billion
Ceres and Shell announce electrolyser agreement for green hydrogen
Cloudflare R2 Storage directly challenges Amazon S3

Tech Events

MIT Technology Review hosts Future Compute February 10-11, 2021
Data+AI Summit, June 27-30, 2022
DesignCon 2021, August 16-18, 2021, San Jose McEnery Convention Center
KubeCon + CloudNativeCon EU, May 4-7, 2021
The global State of Open Data Policy Summit takes place on Tuesday, 17 May from 17 CET!

Footer

Recent Posts

  • Plant-based food innovation company, TMRW Foods, raises C$2 million and prepares for North American launch with Sprouts Farmers Market
  • How to achieving gender balance in management teams
  • When you feel like you’re spiraling
  • After Successful Tax Season, Embedded Tax Platform April Raises $30M Series A from Fintech Veterans
  • Vita Mojo Raises US$30 Million to Help Restaurant and Hospitality Chains in Europe Tackle the Digital Future
  • Nautical Commerce Raises $30M to Scale Multi-Vendor Marketplace Technology
  • Token Announces $13 Million Series B Funding Round and Appointment of New CEO to Disrupt the Authentication Market
  • Konnecto Raises $21M to establish a new category in marketing technology
  • Sharebite, the Leading Food Benefits Platform, Announces Closing of $39 Million Series B Round
  • Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health

Dossier

Square, Inc. Announces Plans to Acquire Afterpay, Strengthening and Enabling Further Integration Between its Seller and Cash App Ecosystems
Microsoft acquires privileged access management vendor CloudKnox Security
Corporate debt as a share of GDP at around 80%
An approach to M&A that created more long-term value
Goodyear to Acquire Cooper, Creating Stronger U.S.-Based Leader in Global Tire Industry

Press Media Release

PUBLIC SERVICES INTERNATIONAL LAUNCHES INTERACTIVE DOCUMENTARY EXPERIENCE ON GLOBAL HEALTH WORKERS
Space Control Veteran Rob Baker Joins System High as Vice President, Strategic Space Protection
Coding Digest
USAFIS: President Biden Gives Big Boost to U.S. Immigration
Texas A&M University System Regents Approve $70 million Engineering Building for Prairie View A&M University

App Coding

Configit Introduces Breakthrough System-Level Configuration Solution
Distraction-free coding
Datadog Named a Leader in the 2022 Gartner® Magic Quadrant™ for Application Performance Monitoring and Observability
Code Intelligence raises $12M Series A
Browser innovation has stalled

API Coding

DataGrail Launches API & Agent to Automate DSR Fulfillment Across All Internal Data Systems, Saving Companies Weeks of Engineering Time
Difference between REST and GraphQL
LeadDev London! The event for engineering leaders
Apiiro Extends Right from Code to Runtime To Help Developers Fix Risks Faster
Web3 can take power and control from BigTech

Copyright © 2022 3v.org

Technologies, Market Analysis & Market Research

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT